Multi-modular Motion-assisted Memory Desensitization and Reconsolidation (3MDR) as treatment for Posttraumatic Stress Disorder

Multi-modular Motion-assisted Memory Desensitization and Reconsolidation (3MDR) as treatment for Posttraumatic Stress Disorder - 3MDR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44897

Enrollment

Registered

2015-04-01

Start date

2015-05-27

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic Stress Disorder PTSD

Interventions

Participants will either receive six 3MDR treatment sessions followed by ten weeks of TAU or will receive sixteen weeks of TAU, other than a trauma-focused psychotherapy. TAU interventions may for i

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Current chronic combat-related Posttraumatic Stress Disorder (Clinician Administered PTSD Scale (CAPS) score > 50, for at least 3 months). - Being treatment resistant for trauma-focused psychotherapeutic interventions, which means having been treated for PTSD for a minimum of 6 consecutive months, of which 3 months with trauma-focused therapy, for instance Eye-Movement Desensitization Reprocessing (EMDR), Brief Eclectic Psychotherapy (BEP), Narrative Exposure Therapy (NET) or Prolonged Exposure (PE) with weekly sessions of at least 45 minutes or two-weekly session of at least 90 minutes.

Exclusion criteria

Exclusion criteria: * Acute suicidality * Difficulties walking, especially on a treadmill * Current severe alcohol and/or substance dependence according to DSM-IV (patients are allowed to enter after initial treatment of this disorder). * Acute psychosis. * Patients must be stable on their current psychotropic medication for a period of 4 weeks before entering the trial and agree to not make changes in dosages or add any new medications during the course of the 3MDR treatment. In agreement with clinical guidelines patients were allowed to stop anxiolytic medication to better engage in trauma processing.

Design outcomes

Primary

Measure	Time frame
Main study parameter is the difference between the two groups in change in PTSD symptom severity between start of the intervention and end of the study.	—

Secondary

Measure	Time frame
Other areas in which improvement is expected are perceived social support, anxiety in general, depressive symptoms, avoidance of thoughts and behaviors, and neuropsychological functioning (memory and attention).	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)